FDAは,EGFR型肺がんの予防接種を初めて承認し,より速くより安全なケアを提供する. FDA approves first subcutaneous treatment for EGFR-mutated lung cancer, offering faster, safer care.

FDAはEGFR変異の非小細胞肺がんを成人に投与する最初の皮膚下治療としてRybrevant Faspro (アミバンタマブとヒアルロンジダゼ- lpuj) を承認し,静脈内療法より迅速で便利な代替治療を提供している. The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first subcutaneous treatment for adults with EGFR-mutated non-small cell lung cancer, offering a faster, more convenient alternative to intravenous therapy. フェーズ3の試験データに基づいて,小分型型は薬物レベルのIV版と一致し,進行性・全体的生存率が向上し,流動性反応や血液凝固が少ないことを示した. Based on Phase 3 trial data, the subcutaneous form matched the IV version in drug levels and showed improved progression-free and overall survival, with fewer infusion-related reactions and blood clots. Lazcluzzeでの第一行使用を含め,すべての治療設定に承認され,治療時間を時間から分まで短縮する. It is now approved for all treatment settings, including first-line use with Lazcluze, and reduces treatment time from hours to minutes.